No. Vivio^® is designed to identify if patients who are at-risk for heart failure have elevated LVEDP – the clinical hallmark of heart failure – and get them started on frontline GDMT as soon as possible. Vivio is useful in that it is highly sensitive to finding early stage heart failure and is easy-to-use at the primary care setting. With its higher sensitivity, Vivio will identify patients with elevated filling pressures that an echo may not detect, which enables earlier and more widespread GDMT utilization. While the Vivio can be used as a standalone to diagnose heart failure, the echo may be helpful for characterizing functional issues in segments of the population, for example, to determine if the type of heart failure is HFpEF or HFrEF. Both echocardiography and cardiac catheterization provide information beyond elevated LVEDP.